Orion Biotechnology is focused on unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs), particularly those associated with obesity and metabolic disorders. The company aims to develop next-generation therapeutics by designing precision-engineered analogs of natural ligands that effectively engage GPCRs. Their proprietary PROcisionX™ discovery platform enhances the efficiency of drug discovery, allowing for the rapid identification and optimization of lead compounds in less than six months. This platform utilizes innovative techniques such as streamlined phage display and multiplex chemical synthesis to generate a diverse library of candidate molecules, which are then evaluated for their pharmacological properties.

The company is advancing a portfolio of potential first-in-class and best-in-class GPCR-targeted therapeutics, with a particular emphasis on the GPR75 receptor, which has shown promise in preclinical evaluations for obesity treatment. Orion's approach not only addresses the significant number of undrugged GPCRs but also aims to overcome existing limitations in GPCR drug discovery and development. By leveraging their expertise in GPCR pharmacology and protein engineering, Orion is positioned to deliver differentiated therapies that could significantly impact the treatment landscape for metabolic disorders.

Canada

Orion is a clinical stage company leveraging a proprietary technology platform to develop next generation therapeutics for effectively targeting G Protein-Coupled Receptors (GPCRs). Orion’s platform enables effectively targeting previously undruggable complex GPCRs. Our pipeline includes 3 next generation therapeutics for cancer including our lead candidate - OB-002 – which is a first-in-class cancer immunotherapy with best-in-class potency.

Orion Biotechnology

Company Details